Alnylam Pharmaceuticals
VP, US Business Lead (Finance)
VP, US Business Lead, Givosiran & Lumasiran
Overview
Alnylam is the industry leader in the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to address the unmet needs of patients with debilitating diseases. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipeline of investigational RNAi therapeutic medicines, including five programs in late-stage development. In 2018, Alnylam received approval for our first product, the first-ever RNAi therapeutic, by the FDA in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and by the European Medicines Agency in the EU for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. Headquartered in Cambridge, Mass., Alnylam employs over 1,200 people in 18 countries and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe's Top Places to Work four years in a row (2015-2018) and a Great Place to Work in the U.K. and Switzerland in 2019. Please visit www.alnylam.com for more information.
The company is preparing for multiple commercial launches in rare and orphan diseases and is currently building its commercial capabilities. Givosiran is currently in late stage development for the treatment of several Acute Hepatic Porphyrias (AHPs). Acute Hepatic Porphyrias represent a sub-group of Porphyrias, characterized by the occurrence of neuro-visceral attacks with or without cutaneous manifestations. Acute Hepatic Porphyrias encompass four diseases: acute intermittent porphyria (the most common), variegate porphyria, hereditary coproporphyria, and hereditary deficit of delta-aminolaevulinic acid dehydratase (extremely rare).
Lumasiran (formerly known as ALN-GO1) is an investigational RNAi therapeutic targeting glycolate oxidase (GO) in development for the treatment of Primary Hyperoxaluria Type 1 (PH1). Lumasiran is designed to reduce hepatic levels of the GO enzyme, thereby depleting the substrate necessary for the production of oxalate - the metabolite that directly contributes to the pathophysiology of PH1. Lumasiran utilizes Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. Lumasiran has received both U.S. and EU Orphan Drug Designations, a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), and a Priority Medicines (PRIME) designation from the European Medicines Agency (EMA). The safety and efficacy of lumasiran have not been evaluated by the FDA, EMA or any other health authority.
We are seeking a seasoned commercial leader who is passionate about science and deeply motivated by the quest of delivering value to patients and their families. Reporting to the SVP, Head of US Region, the successful candidate will lead Alnylam's second and third product launches (Givosiran & Lumasiran respectively) in the US and be responsible for their commercialization through oversight of our field-based Business Account Executive organizations with deep coordination across Alnylam Assist (our in-house Patient Services team), field reimbursement, training and commercial operations. He/she will partner closely with the US Marketing teams across all activities and coordinate field operations with Medical Affairs. This position is located in Cambridge, MA.
Summary of Key Responsibilities
The VP, US Business Lead, Givosiran & Lumasiran will support development of the field structure and customer facing strategies to successfully launch Givosiran & Lumasiran and ensure flawless coordination across Commercial, Medical Affairs and all additional supporting teams:
Qualifications
Expectations, Key Skills and Competencies
Alnylam Pharmaceuticals is an EEO employer committed to an exciting, diverse, and enriching work environment.
*We are not accepting search firm or agency inquiries for this opportunity